Abstract
With the introduction of direct-acting oral antiviral agents we are on the verge of a new era that will transform the treatment landscape. This review discusses recent developments in drug discovery for hepatitis C protease inhibitors. First generation protease inhibitors will offer higher sustained viral response rates in naïve populations when combined with standard pegylated interferon and ribavirin. However, these dramatic gains will be partially offset by new challenges in viral resistance and increased adverse events.
© 2011 John Wiley & Sons A/S.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antiviral Agents / therapeutic use*
-
Drug Therapy, Combination / methods
-
Hepacivirus / drug effects
-
Hepacivirus / genetics*
-
Hepatitis C / drug therapy*
-
Hepatitis C / genetics
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use
-
Interferons
-
Interleukins / genetics
-
Oligopeptides / therapeutic use*
-
Polyethylene Glycols / therapeutic use
-
Proline / analogs & derivatives*
-
Proline / therapeutic use
-
Protease Inhibitors / therapeutic use*
-
Recombinant Proteins
-
Ribavirin / therapeutic use
Substances
-
Antiviral Agents
-
interferon-lambda, human
-
Interferon alpha-2
-
Interferon-alpha
-
Interleukins
-
Oligopeptides
-
Protease Inhibitors
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
telaprevir
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Interferons
-
Proline
-
peginterferon alfa-2a